WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 585127
Description: SX 3228 is a selective ligand for the BZ1 receptor and potent hypnotic when given to the rat during the dark period of the light-dark cycle.
MedKoo Cat#: 585127
Name: SX 3228
Chemical Formula: C18H18N4O3
Exact Mass: 338.1379
Molecular Weight: 338.367
Elemental Analysis: C, 63.89; H, 5.36; N, 16.56; O, 14.18
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: SX 3228; SX-3228; SX3228
IUPAC/Chemical Name: 1,6-Naphthyridin-2(1H)-one, 5,6,7,8-tetrahydro-3-(5-methoxy-1,3,4-oxadiazol-2-yl)-6-(phenylmethyl)-
InChi Key: BZLLVTYOOJNQIF-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H18N4O3/c1-24-18-21-20-17(25-18)14-9-13-11-22(8-7-15(13)19-16(14)23)10-12-5-3-2-4-6-12/h2-6,9H,7-8,10-11H2,1H3,(H,19,23)
SMILES Code: O=C1NC2=C(CN(CC3=CC=CC=C3)CC2)C=C1C4=NN=C(OC)O4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 338.367 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Alvariño F, Monti JM, Jantos H, Monti D. Effect of SX-3228, a selective ligand for the BZ1 receptor, on sleep and waking during the light-dark cycle in the rat. Braz J Med Biol Res. 1999 Aug;32(8):1007-14. PubMed PMID: 10454763.
2: Griebel G, Perrault G, Sanger DJ. Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. J Psychopharmacol. 1998;12(4):356-65. PubMed PMID: 10065909.
3: Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ. Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands. Behav Pharmacol. 1999 Sep;10(5):483-95. PubMed PMID: 10780255.
4: Sanger DJ. The effects of new hypnotic drugs in rats trained to discriminate ethanol. Behav Pharmacol. 1997 Aug;8(4):287-92. PubMed PMID: 9832988.
5: Fujita M, Himi S, Handa T. Effects of compression and grinding on chemical stability of a benzodiazepine receptor agonist. Chem Pharm Bull (Tokyo). 2010 Jan;58(1):51-5. PubMed PMID: 20045966.
6: Fujita M, Himi S, Iwata M. Stabilization study on a wet-granule tableting method for a compression-sensitive benzodiazepine receptor agonist. Chem Pharm Bull (Tokyo). 2010 Mar;58(3):359-62. PubMed PMID: 20190441.
7: Ohta T. [Recent progress in development of psychotropic drugs (5)--Hypnotics]. Nihon Shinkei Seishin Yakurigaku Zasshi. 1996 Oct;16(5):161-70. Review. Japanese. PubMed PMID: 8962434.